Mycobacterium tuberculosis espB monoclonal antibody, preparation method and application thereof

By preparing monoclonal antibodies against Mycobacterium tuberculosis EspB and screening them using phage antibody library technology, the problem of Mycobacterium tuberculosis survival in macrophages has been solved, providing a highly sensitive and specific detection tool with potential therapeutic advantages.

CN122444866APending Publication Date: 2026-07-24BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510103410.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-01-22
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

In the current technology, Mycobacterium tuberculosis is resistant to the host's natural immunity, especially in surviving and multiplying in macrophages, making the disease difficult to control. Existing vaccines and drugs have limited effectiveness, and there is a lack of effective new anti-tuberculosis vaccines and drugs.

Method used

Monoclonal antibodies against Mycobacterium tuberculosis EspB were prepared. High-affinity antibodies were obtained by screening with phage antibody library technology. Animals were immunized with components of the Mycobacterium tuberculosis cell wall to obtain highly specific and high-affinity EspB monoclonal antibodies for detection and potential treatment.

Benefits of technology

The obtained EspB monoclonal antibody has high sensitivity, high specificity and high affinity, and can specifically recognize the EspB protein, avoiding reactions with other tuberculosis antigens, thus providing better detection and potential treatment methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005254777040000081
    Figure BDA0005254777040000081
  • Figure BDA0005254777040000091
    Figure BDA0005254777040000091
  • Figure HDA0005254777050000011
    Figure HDA0005254777050000011
Patent Text Reader

Abstract

The application provides a Mycobacterium tuberculosis EspB monoclonal antibody, a preparation method and application thereof, and relates to the technical field of antibodies. The Mycobacterium tuberculosis EspB monoclonal antibody is obtained by immunizing animals with Mycobacterium tuberculosis cell walls and screening the monoclonal antibody through a phage antibody library technology. The application discloses the Mycobacterium tuberculosis EspB monoclonal antibody or a functional fragment thereof, and application thereof as an antibody conjugate and a composition. The monoclonal antibody has a specific nucleic acid sequence, and codes the specific EspB monoclonal antibody or the functional fragment thereof. The EspB monoclonal antibody obtained by the application has the characteristics of high sensitivity, high specificity and high affinity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the fields of biotechnology and antibody engineering pharmaceuticals, specifically relating to a monoclonal antibody against Mycobacterium tuberculosis EspB, its preparation method, and its application. Background Technology

[0002] Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb) and is a global public health problem. Bacillus Calmette-Guerin (BCG) and anti-tuberculosis drugs have played a crucial role in preventing and treating Mtb infection and reducing TB mortality, resulting in a significant decrease in the number of infected and diagnosed cases, greatly alleviating the TB epidemic and the suffering of many patients. However, the current global threat of TB, and the lack of an effective vaccine to prevent adult TB, suggests that the preventive effect of BCG and the therapeutic effect of anti-tuberculosis drugs are significantly limited and insufficient to address the challenges of the current TB epidemic. This makes the development of new anti-TB vaccines and drugs even more urgent. Currently, our understanding of the pathogenic mechanism of Mycobacterium tuberculosis remains largely incomplete, and the development of new vaccines and drugs faces numerous difficulties. Mycobacterium tuberculosis has a certain resistance to the host's innate immunity. In particular, it can survive and grow in macrophages after being phagocytosed, and cause macrophage death at a certain period of time. This is considered to be one of the important reasons for the pathogenicity of Mycobacterium tuberculosis (Stoop EJ, Bitter W, Vander SAM. Protein secretion systems in Mycobacteria. Trends in Microbiology. 2012; 20(10):477-484).

[0003] The ESX-1 secretion system of Mycobacterium tuberculosis is one of the key factors in this pathogenic process. It has biological functions such as altering cell signal transduction, promoting bacterial escape from macrophage phagosomes, inhibiting phagosome-lysosome fusion, affecting apoptosis and cell lysis, and is closely related to the pathogenicity of Mycobacterium tuberculosis (Simeone R, Bottai D, Brosch R. ESX / type VII secretion systems and their role in host-pathogen interaction. Current Opinion in Microbiology. 2009; 12(1):4-10). It has been confirmed that the ESX-1 secretion system belongs to the type VII secretion system, which contains multiple components encoded by the RD1 (region of difference 1) gene and its surrounding genes, which are missing in the BCG. Some proteins are only involved in the construction of the secretion system, while others are secreted to the bacterial surface through special mechanisms to perform different functions (Abdallah AM, Gey van Pittius NC, Champion PA, et al. Type VII secretion--mycobacteria show the way. Nat Rev Microbiol. 2007; 5(11):883-91). The substrates secreted by the ESX-1 secretion system include: CFP10 (10kDa culture filtrate antigen), ESAT6 (early secreted antigenic target of 6kDa), EspA, EspB, EspC, and EspR. The ESX-1 secretion system is a co-secretion system, characterized by the interdependence of its components, which work together to complete the protein secretion process. If one protein is missing, the secretion and function of other ESX-1 related proteins will inevitably be affected.

[0004] EspB (ESX-1 secretion-associated protein B) is a protein encoded by the Rv3881c gene in the Mycobacterium tuberculosis ESX-1 system. It was first discovered in the homolog Mh3881c of the Mycobacterium marine ESX-1 secretion system and then confirmed in Mycobacterium tuberculosis (Xu J, Laine O, Masciocchi M, et al. A unique Mycobacterium ESX-1 protein co-secretes with CFP-10 / ESAT-6 and is necessary for inhibiting phagosome maturation. Molecular Microbiology. 2007; 66(3):787-800). Like other ESX-1 secretory proteins, EspB is co-secreted with CFP10 and ESAT6. The absence of EspB protein disrupts the secretion of other secretory proteins. During secretion, EspB is cleaved by the protease MycP1 in the periplasmic lumen, forming an 11kDa C-terminus and an approximately 50kDa N-terminus (EspBN). Its C-terminus can directly interact with ESAT-6, which is essential for maintaining intracellular ESAT-6 levels and ESX-1 secretion function. Studies have found that co-secretion of EspB and ESAT-6 can inhibit the maturation of macrophage phagosomes, which is crucial for the survival and growth of Mycobacterium tuberculosis within macrophages. Mutant strains with the EspB gene knocked out almost completely lose virulence, demonstrating the important role of EspB in the pathogenicity of Mycobacterium tuberculosis, its contribution seemingly no less significant than that of ESAT-6. Related research indicates that the inhibition of phagosome maturation by Mycobacterium tuberculosis depends on a secreted ESX-1 protein other than CFP-10 and ESAT-6, and EspB is likely this key molecule. The preparation of EspB antibodies will provide an important reagent reserve for better prevention or treatment of tuberculosis. Summary of the Invention

[0005] This invention utilizes cell wall components extracted from inactivated Mycobacterium tuberculosis H37Rv to immunize Japanese white rabbits. The immunized serum was identified as binding to the tuberculosis antigen EspB, and EspB monoclonal antibodies were successfully obtained through phage antibody library technology for rabbit immunization. Based on this, the invention was completed.

[0006] In a first aspect, the present invention provides a monoclonal antibody or a functional fragment thereof of Mycobacterium tuberculosis EspB protein, said monoclonal antibody comprising a complementarity-determining region (CDR) of a heavy chain (VH) variable region and a light chain (VL) variable region, wherein the amino acid sequence of the heavy chain variable region CDR is as follows:

[0007] The amino acid sequence of VHCDR1 is SEQ ID NO.1; the amino acid sequence of VHCDR2 is SEQ ID NO.2; the amino acid sequence of VHCDR3 is SEQ ID NO.3;

[0008] The amino acid sequence of the CDR region of the light chain variable region is shown below:

[0009] The amino acid sequence of VLCDR1 is SEQ ID NO.4; the amino acid sequence of VLCDR2 is SEQ ID NO.5; and the amino acid sequence of VLCDR3 is SEQ ID NO.6.

[0010] Furthermore, the VH and VL amino acid sequences of the monoclonal antibody or its functional fragment are shown in SEQ ID NO.7 and SEQ ID NO.8, respectively.

[0011] Furthermore, the monoclonal antibody or its functional fragment comprises an antibody constant region Fc, which includes a heavy chain constant region and a light chain constant region.

[0012] Furthermore, the species source of the constant region is mouse, rat, goat, rabbit or human.

[0013] Furthermore, the heavy chain constant region of the monoclonal antibody or its functional fragment is selected from any one of IgD, IgE, IgM, IgA and IgG.

[0014] Furthermore, the heavy chain constant region is IgG, and its amino acid sequence is shown in SEQ ID NO.9.

[0015] Furthermore, the light chain constant region of the monoclonal antibody or its functional fragment is κ or λ type.

[0016] Furthermore, the constant region of the light chain is κ-type, and the amino acid sequence is shown in SEQ ID NO.10.

[0017] Furthermore, the functional fragment is selected from one or more of Fab, Fab', F(ab')2, Fv, Fd, scFv and / or scFv-Fc chimeric fragments and bispecific antibodies.

[0018] In a second aspect, the present invention provides a nucleic acid molecule that encodes a monoclonal antibody or a functional fragment thereof as described in the first aspect of the present invention.

[0019] Furthermore, the nucleotide sequences encoding antibodies VH and VL are shown in SEQ ID NO.11 and SEQ ID NO.12, respectively.

[0020] Thirdly, a vector or host cell comprising nucleotide molecules as described in the second aspect of the invention.

[0021] Fourthly, the present invention provides an antibody conjugate comprising the monoclonal antibody or a functional fragment thereof described in the first aspect of the present invention.

[0022] Fifthly, the present invention provides a composition comprising the monoclonal antibody or a pharmaceutically acceptable carrier thereof as described in the first aspect of the present invention, the nucleic acid molecule as described in the second aspect, the carrier or host cell as described in the third aspect, or the antibody conjugate as described in the fourth aspect.

[0023] In a sixth aspect, the present invention provides the use of a monoclonal antibody or a functional fragment thereof as described in the first aspect, a nucleic acid molecule as described in the second aspect, a vector or host cell as described in the third aspect, an antibody-drug conjugate as described in the fourth aspect, or a composition as described in the fifth aspect in the diagnosis of diseases and in the preparation of medicaments for the prevention and / or treatment of diseases caused by Mycobacterium tuberculosis infection.

[0024] Furthermore, the Mycobacterium tuberculosis infection includes: primary infection, secondary infection, and / or extrapulmonary infection.

[0025] In a seventh aspect, the present invention provides a reagent for detecting Mycobacterium tuberculosis EspB protein, the reagent containing the monoclonal antibody or its functional fragment as described in the first aspect of the present invention, the nucleic acid molecule as described in the second aspect, the vector or host cell as described in the third aspect, the antibody conjugate as described in the fourth aspect, or the composition as described in the fifth aspect.

[0026] Eighthly, the present invention provides a kit for detecting Mycobacterium tuberculosis EspB protein, the kit comprising instructions and detection reagents, wherein the detection reagents are those described in the seventh aspect of the present invention.

[0027] Furthermore, the kit can be prepared as an ELISA detection kit and / or a colloidal gold detection kit.

[0028] Furthermore, the diagnostic methods of the kit include direct methods, indirect methods, double-antibody sandwich methods, and / or competitive methods.

[0029] Ninthly, the present invention provides a method for preparing a monoclonal antibody against Mycobacterium tuberculosis EspB, the method comprising the following steps:

[0030] S1. Extract and identify the cell wall of Mycobacterium tuberculosis. If the identification is correct, use it for immunization.

[0031] S2. Immune animals using the cell wall extracted in step S1;

[0032] S3. Measure serum titer after immunization in step S2;

[0033] S4. Blood was obtained from animals after the last immunization to identify the reactivity of the immune serum with tuberculosis antigen;

[0034] S5. Use phage antibody library technology to screen for EspB monoclonal antibodies to obtain the EspB monoclonal antibodies of the present invention;

[0035] S6. Construct the full-length heavy chain and full-length light chain expression vectors of the monoclonal antibody EspB of the present invention, respectively;

[0036] Expression and purification of S7.EspB monoclonal antibody.

[0037] Furthermore, in step S1, the mycobacterial cell wall is preferably the cell wall of Mycobacterium tuberculosis.

[0038] Furthermore, in step S1, the cell wall component identification methods include, but are not limited to, ELISA and protein immunoblotting.

[0039] Furthermore, the immunized animal in step S2 is the Japanese giant rabbit.

[0040] Furthermore, in step S2, the immunity includes basic immunity and booster immunity.

[0041] Furthermore, the basic immunization is performed by emulsifying cell wall components with an equal volume of Freund's complete adjuvant, and the booster immunization is performed by emulsifying cell wall components with an equal volume of Freund's incomplete adjuvant, for a total of four immunizations.

[0042] Beneficial effects

[0043] This invention utilizes the cell wall of Mycobacterium tuberculosis to immunize animals. Compared to immunization using purified protein, it exhibits better immunogenicity; compared to immunization using inactivated Mycobacterium tuberculosis, it has lower lethality in immunized animals. It also eliminates the need for large-scale expression and purification of EspB protein for immunization, making it more cost-effective. By screening EspB antibodies using phage antibody library technology, high-affinity antibodies are more easily obtained compared to traditional hybridoma technology. The prepared EspB monoclonal antibody exhibits high sensitivity, high specificity, and high affinity, reacting only with EspB protein and not with other tuberculosis antigens such as LAM, Mtb8, and Ag85B-HBHA, and can be used to detect Mycobacterium tuberculosis EspB protein. Attached Figure Description

[0044] Figure 1 ELISA was used to identify the specificity of rabbit immune serum.

[0045] Figure 2 The purity of EspB monoclonal antibody was determined by SDS-PAGE electrophoresis.

[0046] Figure 3 ELISA was used to identify the specificity of EspB monoclonal antibodies.

[0047] Figure 4 ELISA identification of EspB monoclonal antibody for EspB protein detection sensitivity.

[0048] Figure 5 Protein immunoblotting to identify the binding properties of EspB monoclonal antibodies to EspB protein. M: Protein Marker; EspB:

[0049] EspB protein.

[0050] Figure 6 Identification of LAM antibody affinity; the curves in the figure represent the antibody concentrations from top to bottom as follows: 250nM / 125nM / 62.5nM / 31.2nM / 15.6nM / 7.8nM. Detailed Implementation

[0051] The specific embodiments of the present invention will be further described below. It should be noted that these descriptions are for the purpose of aiding understanding the present invention, but do not constitute a limitation thereof. Furthermore, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0052] Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods, and the experimental materials used in the following embodiments are all available through conventional commercial channels.

[0053] Test materials

[0054] Coating solution (BD OptEIA Coating Buffer, 51-2713KC): 0.1M sodium carbonate at pH 9.5;

[0055] Washing solution (BD OptEIAWash Buffer, 51-9003739): 20× concentrated washing solution should be diluted with deionized water or distilled water to make a 1× working solution;

[0056] Developing solution A (BD OptEIA Substrate Reagent A, 51-2606KZ): a buffer solution containing hydrogen peroxide;

[0057] Colorimetric solution B (BD OptEIA Substrate Reagent B, 51-2607KZ): An organic solvent containing 3,3',5,5'-tetramethylbenzidine (TMB);

[0058] Stop solution (BD OptEIA Stop Solution, 51-2608KZ): 1 part sulfuric acid;

[0059] Blocking solution: 5% skim milk, 5 grams of milk added to 100 ml of 1×PBS solution.

[0060] Example 1: Preparation of Rabbit Anti-EspB Monoclonal Antibody

[0061] (1) Preparation and identification of the cell wall of Mycobacterium tuberculosis H37Rv

[0062] Mycobacterium tuberculosis H37Rv was cultured in Middlebrook 7H9 medium until the logarithmic growth phase. The cells were collected by centrifugation, washed, and inactivated. The bacteria were lysed, and any undystomped bacteria were removed by low-speed centrifugation. The supernatant was collected by high-speed centrifugation to collect cell wall components, and the concentration was determined by UV spectrophotometry. The extracted cell wall components were identified, and those correctly identified were used for immunization.

[0063] (2) H37Rv bacterial cell wall extract immunization of Japanese rabbits

[0064] Japanese white rabbits were selected. Blood was collected from the marginal ear vein, centrifuged, and the supernatant serum was collected and stored for testing. For primary immunization, 200 μg of cell wall components was emulsified with an equal volume of Freund's complete adjuvant and injected via the plantar fossa. Booster immunizations were performed 2-3 weeks later using an equal volume of cell wall components emulsified with Freund's incomplete adjuvant and injected via the popliteal lymph node. A total of four immunizations were administered. Serum titers were determined one week after the third and fourth immunizations.

[0065] (3) Detection of serum titer in immunized rabbits

[0066] EspB protein was diluted with coating buffer and coated onto a 96-well microplate overnight. After washing and blocking, serially diluted samples (PBST-5% skim milk powder and sample diluent) were added and reacted. After washing, goat anti-rabbit-HRP antibody diluted 1:5000 was added and reacted. After washing, chromogenic buffer was added and reacted; once development was complete, stop buffer was added. The microplate reader was used for OD... 450 Readings. Serum after immunization was diluted 1:25000 and tested positive by ELISA.

[0067] (4) Collection and storage of immune serum

[0068] Nine days after the last immunization, the animals were anesthetized and euthanized; blood was collected, centrifuged, and the supernatant serum was collected and frozen for later use.

[0069] (5) ELISA method for identifying the reactivity of immune serum with tuberculosis antigen

[0070] Experimental Procedure: ELISA plates were coated with 1 μg / ml of tuberculosis-specific antigens LAM, 38KD, MPT32, MPT64, EspB, Rv3878, Rv3872, Mtb8, EspC, Rv0222, Rv3425, CFP21, ORF14, CFP10-Mtb8-EspC, and Ag85B-HBHA and incubated overnight. The plates were washed and blocked with PBST-5% skim milk powder. After washing, primary antibody was added to 1:5000 diluted immune serum; after washing, secondary antibody was added to 1:5000 diluted goat anti-rabbit-HRP antibody, and the reaction was initiated. The plates were washed, patted dry, and substrate was added. The reaction was stopped after 10 min. After color development, stop solution was added, and the plates were readjusted using an OD1000 microplate reader. 450 reading.

[0071] Results: Cell wall-immunized rabbit serum reacted with LAM, Mtb8, and EspB, but did not react with other tuberculosis antigens 38KD, MPT32, MPT64, Rv3878, Rv3872, EspC, Rv0222, Rv3425, CFP21, ORF14, CFP10-Mtb8-EspC, and Ag85B-HBHA. Figure 1 ).

[0072] (6) Screening of EspB monoclonal antibodies using phage antibody library technology

[0073] Construction and screening of rabbit monoclonal antibody scFv phage antibody library: Rabbit tissue (spleen or bone marrow) was collected for RNA extraction. The variable region (V) gene of the antibody was amplified by RT-PCR. Then, the heavy chain and light chain variable regions (VH and VL) fragments were spliced ​​to obtain the fused scFv fragment, which was inserted into an expression vector. The cells were electroporated into competent cells to obtain a phage antibody library with a volume of at least 10⁻⁶ cells / mL. 9 The phage antibodies to be screened were co-incubated with the coating antigen. After multiple rounds of washing and elution, enriched specific binding phages were obtained and amplified and cultured. The supernatant was used for ELISA detection. Clones with different band patterns were selected for ELISA retesting. Those that were still positive were subjected to antibody sequencing.

[0074] Construction and expression of the complete rabbit anti-LAM-IgG antibody sequence: The variable region sequence of the antibody was obtained by sequencing. The constant region sequence of the rabbit IgG antibody was known, and vectors containing the rabbit antibody constant region were stored. Using overlap PCR technology, the full-length sequences of the heavy and light chains were amplified using screened clones and vectors containing the antibody constant region sequence as templates to construct expression vectors for the IgG antibody heavy chain (pCMV3-H) and light chain (pCMV3-L). The expression vectors were transiently transfected into HEK293 cells. 6-7 days after transfection, the supernatant was collected and purified by protein A to obtain purified antibodies. Further studies were conducted after the purified antibodies were identified.

[0075] Example 2: EspB antibody sequence analysis

[0076] 2.1 Amino acid sequence of the CDR region of EspB monoclonal antibody

[0077] Amino acid sequence analysis of the variable region of the antibody confirmed one EspB monoclonal antibody, named BJRb-EspB, through phage antibody library screening using scFv. Positive clones were sequenced to obtain the light and heavy chain variable region sequences. Analysis using IGBLAST software (https: / / www.ncbi.nlm.nih.gov / igblast / ) revealed that the scFv antibody belongs to the VH class and Vκ type. Further analysis of the three CDR regions (VH (heavy chain variable region) and VL (light chain variable region) of each antibody using ABodyBuilder software (http: / / opig.stats.ox.ac.uk / webapps / newsabdab / sabpred / abodybuilder / ) in Kabat mode further analyzed the positions of the three CDR regions. The amino acid sequences of BJRb-EspB-VHCDR1-3 are shown in SEQ ID NO. 1-3; the amino acid sequences of BJRb-EspB-VLCDR1-3 are shown in SEQ ID NO. 4-6.

[0078] 2.2 Amino acid sequences of the heavy and light chain variable regions of the BJRb-EspB antibody

[0079] The amino acid sequences of VH and VL of BJRb-EspB are shown in SEQ ID NO.7 and SEQ ID NO.8, respectively; the amino acid sequence of the heavy chain constant region of BJRb-EspB is shown in SEQ ID NO.9; and the amino acid sequence of the light chain constant region of BJRb-EspB is shown in SEQ ID NO.10.

[0080] 2.3 Nucleotide sequence encoding the antibody

[0081] The nucleotide sequences encoding the variable region of the antibody heavy chain (underlined sequences are signal peptide encoding sequences): The VH and VL nucleotide sequences of BJRb-EspB are shown in SEQ ID NO.11 and SEQ ID NO.12, respectively.

[0082] The nucleotide sequence of the heavy chain constant region encoded by BJRb-EspB is shown in SEQ ID NO.13; the nucleotide sequence of the light chain constant region encoded by BJRb-EspB is shown in SEQ ID NO.14.

[0083] Table 1. Sequence List of SEQ ID NO.1-SEQ ID NO.14

[0084]

[0085]

[0086] Example 3: Expression, purification, and identification of EspB monoclonal antibody

[0087] The antibody light chain and heavy chain expression vectors were simultaneously and transiently transfected into HEK293 cells. One week after transfection, the culture supernatant was collected and purified using a protein A purification column to obtain purified antibodies. The antibody molecular weight was predicted, and the purity and molecular weight were identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

[0088] SDS-PAGE detection results ( Figure 2 The predicted molecular weight of the antibody heavy chain is approximately 47 kDa, the predicted molecular weight of the light chain is approximately 23 kDa, and the predicted molecular weight of the full IgG antibody is approximately 140 kDa. SDS-PAGE electrophoresis confirmed that the protein molecular weight is close to the predicted molecular weight, and the antibody purity is good, around 94%. Figure 2 In the diagram, A represents the detection result under non-reduction conditions; B represents the detection result under reduction conditions; and M represents the marker.

[0089] Example 4: ELISA method for identifying the specificity of BJRb-EspB monoclonal antibody

[0090] Experimental Procedure: Coat ELISA plates with 1 μg / ml of tuberculosis-specific antigens EspB, LAM, Mtb8, and Ag85B-HBHA overnight. Wash and block with PBST-5% skim milk powder. Wash again, add 1 μg / ml of BJRb-EspB as primary antibody; wash again, add 1:5000 diluted goat anti-rabbit-HRP antibody as secondary antibody, and react. Wash, pat dry, add substrate, and stop the reaction after reaction. After color development, add stop solution and readjust the ELISA plate using an OD1000 reader. 450 reading.

[0091] Experimental results: BJRb-EspB reacts only with EspB protein and does not react with other tuberculosis antigens LAM, Mtb8, and Ag85B-HBHA. Figure 3 ).

[0092] Example 5: ELISA method for identifying the sensitivity of EspB monoclonal antibody

[0093] Experimental procedure: EspB protein was serially diluted 10 times with coating buffer and used to coat the ELISA plate overnight. 1 μg / ml of BJRb-EspB was added as primary antibody; a 1:5000 dilution of goat anti-rabbit-HRP antibody was added as secondary antibody. The remaining steps were the same as the ELISA procedure described above.

[0094] Experimental results: The sensitivity of BJRb-EspB to EspB protein was 100 ng / ml. Figure 4 ).

[0095] Example 6: Protein Immunoblot Identification of BJRb-EspB Monoclonal Antibody Binding to EspB Protein

[0096] Experimental Procedure: EspB-His recombinant protein was mixed with loading buffer and boiled. Separation was performed by SDS-PAGE gel electrophoresis. The target fragment was electrotransferred from the PAGE gel to a nitrocellulose membrane. The membrane was blocked. EspB monoclonal antibody was added for reaction; the membrane was washed. Horseradish peroxidase-labeled goat anti-rabbit IgG was added for reaction. After washing the membrane, chemiluminescent substrate was added, and the results were recorded using a gel imaging system.

[0097] Results of protein immunoblotting detection for BJRb-EspB monoclonal antibody recognition of Esb ( Figure 5 In protein immunoblotting assays, BJRb-EspB monoclonal antibody can react with recombinant EspB protein. Figure 5 In the text, M stands for Protein Marker; EspB stands for EspB protein.

[0098] Example 7: EspB Monoclonal Antibody Affinity

[0099] Antibody affinity was detected using the ForteBio Octet molecular interaction instrument. The EspB-His recombinant protein was used as the antigen for detection, and the ForteBio Anti-penta-HIS capture biosensor (HIS1K) was applied.

[0100] Affinity test results ( Figure 6 Antibody affinity was determined using the ForteBio Octet system, with a buffer solution without EspB-His protein as a blank control. After data analysis, the antibody affinity KA was determined. D The values ​​are 9.74 × 10 -10 M, curve fit goodness of fit R 2 They are 0.9817 respectively.

Claims

1. A monoclonal antibody against Mycobacterium tuberculosis EspB protein or a functional fragment thereof, said monoclonal antibody comprising a complementarity-determining region (CDR) of a heavy chain (VH) variable region and a light chain (VL) variable region, wherein the amino acid sequence of the heavy chain variable region CDR is as follows: The amino acid sequence of VHCDR1 is SEQ ID NO.1; the amino acid sequence of VHCDR2 is SEQ ID NO.2; the amino acid sequence of VHCDR3 is SEQ ID NO.3; The amino acid sequence of the CDR region of the light chain variable region is shown below: The amino acid sequence of VLCDR1 is SEQ ID NO.4; the amino acid sequence of VLCDR2 is SEQ ID NO.5; and the amino acid sequence of VLCDR3 is SEQ ID NO.

6.

2. The monoclonal antibody or its functional fragment as described in claim 1, characterized in that, The VH and VL amino acid sequences of the antibody or its functional fragment are shown in SEQ ID NO.7 and SEQ ID NO.8, respectively.

3. The monoclonal antibody or its functional fragment as described in claims 1-2, characterized in that, The heavy chain constant region is selected from the heavy chain constant region of any one of the antibodies IgD, IgE, IgM, IgA and IgG; the light chain constant region of the antibody or its functional fragment is a κ-type or λ-type light chain constant region; the functional fragment is selected from one or more of Fab, Fab', F(ab')2, Fv, Fd, scFv, scFv-Fc chimeric fragments and bispecific antibodies.

4. A nucleic acid molecule, said nucleic acid molecule encoding a monoclonal antibody or a functional fragment thereof as described in any one of claims 1-3.

5. A vector or host cell comprising the nucleotide molecule as described in claim 4.

6. An antibody conjugate comprising the monoclonal antibody or a functional fragment thereof as described in claims 1-3.

7. A composition comprising the monoclonal antibody or a functional fragment thereof as claimed in claims 1-3, the nucleic acid molecule as claimed in claim 4, the vector or host cell as claimed in claim 5, or the antibody conjugate as claimed in claim 6.

8. The use of the Mycobacterium tuberculosis EspB monoclonal antibody or its functional fragment as described in any one of claims 1-3, the nucleic acid molecule as described in claim 4, the vector or host cell as described in claim 5, the antibody conjugate as described in claim 6, and / or the composition as described in claim 7 in the diagnosis of diseases and in the preparation of medicaments for the prevention and / or treatment of diseases caused by Mycobacterium tuberculosis infection.

9. A kit for detecting EspB protein in Mycobacterium tuberculosis, characterized in that, The kit comprises one or more of the antibodies or functional fragments thereof as described in claims 1-3, the nucleic acid molecules as described in claim 4, the vectors or host cells as described in claim 5, the antibody conjugates as described in claim 6, and the compositions as described in claim 7.

10. A method for preparing a monoclonal antibody against Mycobacterium tuberculosis EspB, the method comprising the following steps: S1. Extract and identify the cell wall of Mycobacterium tuberculosis. If the identification is correct, use it for immunization. S2. Immune animals using the cell wall extracted in step S1; S3. Measure serum titer after immunization in step S2; S4. Blood was obtained from animals after the last immunization to identify the reactivity of the immune serum with tuberculosis antigen; S5. Use phage antibody library technology to screen EspB monoclonal antibodies to obtain the EspB monoclonal antibody of this invention; S6. Construct the full-length heavy chain and full-length light chain expression vectors of the monoclonal antibody EspB of the present invention, respectively; Expression and purification of S7.EspB monoclonal antibody.